JNJ-79635322

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
180 patients (estimated)
Sponsors
Janssen Research & Development LLC
Tags
B-Cell Maturation Antigen (BCMA), CD3, GPRC5D, Tri-specific Antibody
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1883
NCT Identifier
NCT05652335

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.